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SUMMARY 
There is increasing professional and policy interest in the role of clinical guidelines for 
promoting effective and efficient health care.  The NHS Health Technology Assessment 
Programme identified an urgent need, when such guidelines are produced, to develop a 
framework and methods for incorporating the best evidence of effectiveness, taking into 
account information on cost-effectiveness.  This paper describes the development of recent 
evidence-based guidelines, for use in primary care, which were the result of recent work by 
the North of England Guidelines Development Group.  Their specific aim was to incorporate 
economic analysis into the guideline process and treatment recommendations.  The 
introduction of economic data raised some methodological issues, specifically: in providing 
valid and generalisable cost estimates; in the grading of cost ‘evidence’; in finding a 
presentation helpful to clinicians.  The approach used was to help clinicians  aggregate the 
various attributes of treatment to make good treatment recommendations, rather than interpret 
cost-effectiveness ratios.  In none of the guideline areas was there adequate information to 
estimate a cost per quality-adjusted-life-year.  In the light of this research, future areas of 
work are identified and some recommendations are made for the forthcoming National 
Institute for Clinical Excellence. 
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INTRODUCTION 
The recent consultative document ‘A first class service: quality in the new NHS’ outlines 
plans for the establishment of a new National Institute for Clinical Excellence (NICE). [1]  
The objective of NICE is ‘to give new coherence and prominence to information about 
clinical and cost-effectiveness’ and to ’produce and disseminate clinical guidelines, based on 
relevant evidence of clinical and cost-effectiveness’.   
Despite the proliferation of clinical guidelines, most do not address issues of cost-
effectiveness and indeed, there may be unforeseen problems in introducing economic 
‘evidence’ into guidelines.  If recommendations produced by NICE are to lead to more cost-
effective healthcare provision, it is important that any potential problems are addressed 
before NICE begins its work.  This paper provides commentary on an attempt to develop 
evidence-based guidelines that explicitly considered the economic aspects of their 
recommendations.  
A framework for formulating treatment recommendations is presented and the manner in 
which this differs from a common health-economic policy approach are discussed.  The 
methodology of evidence-based guideline development is described briefly, showing the 
process required to include cost-effectiveness concepts.  Examples of recent guideline work, 
addressing the use of ACE-inhibitors and NSAIDs in primary care, is provided and also a 
checklist for health economists becoming involved in guideline work. We will identify the 
strengths and weaknesses of our approach and move on to consider what questions now need 
to be answered, in the context of present health service reforms in the United Kingdom. 
Why have economics in guidelines? 
Within the UK, most guideline development has involved informal consensus processes, 
focusing on issues of clinical effectiveness.  While a number of evidence-based guidelines 
have been published, these still focus on clinical effectiveness. [2-6]  The introduction of cost 
considerations within guidelines has been argued for [7-9], though it is unclear how the 
introduction of economic data would influence the recommendations produced by a guideline 
development group.   
The reasons for considering costs are clearly stated by Eddy [7] ; “health interventions are 
not free, people are not infinitely rich, and the budgets of (health care) programmes are 
limited.  For every dollar’s worth of health care that is consumed, a dollar will be paid.  
Furthermore, the costs will be paid by present and future patients.  Such costs will be paid 
through insurance premiums, smaller employee benefit packages, lower salaries, the cost of 
commodities or direct or indirect taxation.  While these payments can be laundered, disguised 
or hidden, they will not go away.  Therefore, the costs of interventions should be balanced 
against the health outcomes predicted for that intervention for two reasons.  Firstly, at the 
level of individual patients, failure to make the comparison may cause people to receive (and 
thus pay for) interventions that they might otherwise have declined, had they been fully NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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informed.  Secondly, at the level of health care systems, costs must be considered if the 
available resources are to be used efficiently; failure to do this lowers the quality of care and 
harms the health of patients”.   
The Committee on Clinical Practice Guidelines [8] recommends that every set of clinical 
practice guidelines include information on the cost implications of alternative preventive, 
diagnostic, and management strategies for the clinical situation in question.  Their stated 
rationale is that this information can help potential users to better evaluate the potential 
consequences of different practices.  Although they acknowledge “the reality is that this 
recommendation poses major methodological and practical challenges” they suggest that, in 
the process of considering costs, five theoretical questions that should be considered (Box 1) 
going on to  provide reasons why guideline developers will have difficulty finding the 
answers to these questions (Box 2).   
 
Box 1: Issues to be addressed in clinical guidelines. 
•  What evidence suggests that the services are likely to affect 
outcomes for the condition or intervention being considered? 
•  What groups at risk are most likely to experience benefits or 
harms from the proposed course of care and its side effects? 
•  What is known about the effects of different frequencies, 
duration, dosages, or other variations in the intensity of the 
intervention? 
•  What options in the ways services are organised and provided can 
affect the benefits, harms and costs of services? 
•  What benefits, harms and costs can be expected from alternative 
diagnostic or treatment paths, including watchful waiting or no 
intervention? 
Source: Institute of Medicine (1992) [8] 
 
Box 2: Problems confronting guideline developers. 
•  Scientific evidence about benefits and harms is incomplete 
•  Basic, accurate cost data are scarce for the great majority of 
clinical conditions and services 
•  While data on charges may be available, significant analytic steps 
and assumptions are required to treat charge data as cost data 
•  Techniques for analysing and projecting costs and cost 
effectiveness are complex and only evolving 
Source: Institute of Medicine (1992) [8] 
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Once cost issues have been considered in the light of these questions and limitations, there is 
the further question of how to use the data in a guidelines group.  Should it be presented 
alongside recommendations based solely on clinical effectiveness or should it be 
incorporated into the judgement process of deriving recommendations?  Williams [9] argues 
that guidelines based on effectiveness issues and then costed may differ substantially and be 
less efficient than guidelines based on cost effectiveness issues.  The complexity of this 
process, and the reactions it evokes, are reflected by the Committee on Clinical Practice 
Guidelines [8] report of “much debate, and with some vigorous dissent”.  There is no widely 
accepted successful way to incorporate economic considerations into guidelines. 
It is not clear how UK health care professionals will react to this process.  Most health care 
professionals have a limited knowledge of health economics and economic modelling.  
Guidelines based on clinical effectiveness could be enhanced or undermined by the 
incorporation of economic considerations depending on whether they are seen as attempts to 
achieve cost-effectiveness or cost-containment.  Additionally, it is uncertain how the 
incorporation of economic considerations will affect the use of guidelines with individual 
patients, although the intention is to encourage a more explicit consideration of cost 
consequences in each consultation where the guideline is used.  UK health professionals are 
not accustomed to this process at anything other than an implicit level.  Furthermore, with the 
prominence given to systematic reviewing and evidence-based guideline construction [10-
12], it is unclear how “evidence” from the methodology of health economics, with its reliance 
on limited cost data, modelling and assumptions, will sit alongside “evidence” derived from 
the (perceived) rigour of systematic review.  However, the absence of economic data from 
guidelines may severely limit their usefulness to medicine at both the policy and practice 
level. 
At first sight, the values of clinicians seem very different from those of health economists.  
Clinicians, as advocates for patients, want to give the best possible treatment in each 
situation, while economists appear preoccupied with the prudent use of resources.  Clinicians, 
nonetheless, are de facto the decision-makers deciding the allocation of resources and, with 
few exceptions, clinicians may defend their decisions on the basis that they believe they are 
providing appropriate patient care in each situation and with the information available. There 
is scant evidence that economic evaluation in any of its forms has made very much impact 
upon clinical decision-making in the United Kingdom.  However, most of the recent 
reorganisations in the British National Health Service can be considered to be driven (at least 
in part) by economic principles, e.g. general practioner fundholding and hospital trust status. 
Concepts Underpinning Economic Evaluation 
The development of economic evaluation has been driven by concepts of efficiency.  A 
commonly-used objective in publicly provided health care systems is to improve or maintain 
health, as far as possible, with available resources.  To maximise health gains, cost-effective 
strategies in health care must be identified; these are ones that produce, in a therapeutic area, 
the maximum output for a given cost (or minimum cost for a given output).  This criterion NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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alone, though, is inadequate, since to maximise health in the population requires the various 
cost-effective strategies across all therapeutic areas to be implemented in proportions that 
achieve the socially-optimal allocation of resources.  The measurement of health has 
mushroomed as an academic and clinical pursuit in recent years, with one strand attempting 
to produce generic measures that reduce patient health status (and its changes over time) to a 
single index (e.g. the Quality-Adjusted Life-Year or QALY).  Hence, theoretically, health 
gains could be compared across different diseases and patient groups. 
One approach to economic evaluation, the ‘decision-making’ approach, recognises that 
decision-makers have a range of objectives besides efficiency [13 14].  Inputs to decisions 
may include the decision-makers’ personal values and specific notions of equity.  Current 
thought is to provide an index of output efficiency (the cost/QALY) to contribute to the 
decision-making process in the hope that decision-makers will give such data a good weight.  
Literature considering the impact of cost-effectiveness studies shows little impact [15-18] 
and it is possible that such studies may have been misdirected as to their audience.  This may 
have been no bad thing, since the quality of the studies themselves has often been inadequate 
[19-24]. 
The decision-making approach also assumes the existence of an audience of social decision-
makers, interested in weighing the costs and benefits of policy changes to all affected parties, 
and who may apply the results of cost-effectiveness studies.  This assumption may be largely 
invalid in many health care systems.  For example, in the United Kingdom, the foremost role 
of health authorities is (despite a history of reforms) to administer the flow of funds into 
primary and secondary care.  Purchasers contracting for health services (often covering, in 
one service agreement, provision of a whole medical specialty) may have little use for an 
economic evaluation of an individual technology.  In insurance-based systems, economic 
evaluations may be useful to health insurers where reimbursement follows (or can be refused) 
for a specified treatment, but in all health care systems it is the doctor who remains 
responsible for treatment decisions and ideally should own the conclusions of research 
findings.  Thus, clinical practice guidelines offer the potential to resolve societal and 
individual patient-based decision-making, since they address the pertinent audience. 
The rationale underpinning economic evaluation has been the belief that complex cost and 
benefit profiles associated with treatments can be aggregated, thus handing ‘an answer’ to aid 
decision-making (at least with respect to efficiency).  This has proved unproductive, in part 
because the methods and data have not been adequate to provide a simple answer and in part 
because clinicians (the key audience) do not appear to think of appropriate health care in 
terms of economic outcomes, such as cost-effectiveness ratios.  
The areas in which economic analyses have had some impact (formally or informally) are 
licensing and reimbursement decisions for new pharmaceuticals and in the introduction of 
some new ‘big-ticket’ technologies such as heart transplantation [25].  However, there is no 
evidence of impact upon already established health care technologies.  This may generate a 
distortion in health care policy since new technologies are being evaluated with far greater 
stringency than existing care.  The current evidence-based medicine culture potentially 
provides an environment for clinicians to review their existing practice.  In recognition of the CHE Discussion Paper 164 
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ubiquitous constraints on resources, it is important that economic analysis takes the 
opportunity to contribute appropriately to this process.  
Guideline Objectives 
The guidelines development process recognises the clinician as the decision-maker, acting as 
the arbiter of appropriate treatment.  In making decisions, clinicians balance their own 
preferences, those of patients and carers, patient specific information, the benefits, side-
effects and safety of treatment and, to varying extents (depending on the mode of 
reimbursement), cost.  Consequently, the primary goal of guidelines development is not to 
derive a cost per quality-adjusted life-year, rather to help the clinician perform the 
aggregation of attributes of treatment, and develop well-informed social preferences.  Such a 
process still requires the assessment of costs and benefits of treatment to be methodologically 
sound.  The novel aspect is the dynamic use of economic data (rather than as static published 
studies), alongside traditional clinical inputs, in the development of clinician valuation of 
treatments and consequent recommendations. In the rest of this chapter, we describe and 
comment on our initial attempt to introduce economic analysis into the process of developing 
evidence-based clinical practice guidelines. 
DEVELOPING COST CONSCIOUS EVIDENCE-BASED GUIDELINES 
The aim of a guideline is to provide recommendations, evidence-based where possible, to 
inform health care professionals about their use of health technologies.  By constructing 
representative groups to work systematically through available, graded evidence and 
contextual issues, it may be possible to reach treatment recommendations that achieve the 
costs and benefits they predict while reflecting remaining uncertainties.  A guideline does not 
replace the responsibility of health care professionals to use general medical knowledge and 
clinical judgement in consultations. It is recognised that recommendations may not be 
appropriate for use in all circumstances, and decisions to adopt any particular 
recommendation must be made by the practitioner in the light of available resources and 
circumstances presented by individual patients.  
Each guideline involves a systematic appraisal of a medical intervention in terms of the areas 
shown in Box 3. This being the most current, pertinent and complete data available, each 
guideline sets out, or profiles, these attributes of treatment and, where appropriate, attempts a 
robust presentation showing the possible bounds of cost-effectiveness that might result. The 
range of values used to generate low and high cost-effectiveness estimates reflects available 
evidence and the concerns of the guideline development group.  Simple and transparent 
presentation also permits reworking with different values from the ones used by the guideline 
group.  
 NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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Box 3: Areas for systematic appraisal in guidelines. 
•  effectiveness  
•  quality-of-life  
•  compliance 
•  safety 
•  health service delivery issues  
•  resource use  
•  costs in the British health care setting 
 
Our guidelines groups did not feel it helpful to consider a synthesis of previously published 
economic analyses which adopted a variety of differing perspectives, analytic techniques and 
baseline data.  However, the economic literature was reviewed to position guideline findings 
against representative published economic analyses and interpret differences in findings 
when the group found it beneficial. We are unaware of any previous attempt to make formal 
inclusion of recommendations for the efficient use of health service resources in an evidence-
based guideline. Hence, the approach used is recognised to be developmental. 
Guideline Development 
North of England Guidelines Development Groups were convened during 1996-7 to develop 
evidence-based guidelines for primary care prescribing decisions in four clinical areas. These 
guidelines were developed for use within a trial evaluating the effectiveness and efficiency of 
evidence-based outreach visits. Guideline topics were chosen for treatment areas where there 
was perceived to be scope for appropriate change and where guideline messages were likely 
to vary in the scale of changes of costs and benefits involved. The four treatments addressed 
were: ACE-inhibitors in the primary care management of adults with symptomatic heart 
failure; aspirin for the secondary prophylaxis of vascular disease in primary care; the choice 
of antidepressants for depression in primary care; and non-steroidal anti-inflammatory drugs 
(NSAIDs) versus basic analgesia in the treatment of osteoarthritis. [2, 3, 26, 27] 
Guideline development groups were composed of general practitioners (GPs), secondary care 
physicians, local authority medical and pharmaceutical advisers, pharmacists and a research 
team consisting of a guideline development methodologist (ME, who acted as the group 
leader), a systematic reviewer (NF), and a health economist (JM). Clinical members brought 
to the group their knowledge of the disease, experiences in treating patients, and 
understanding of the practicalities of the health care system. The research team (ME, NF, 
JM) were responsible for reviewing and summarising the evidence relating to treatments and 
interactively feeding this information back to the group to allow the development of 
recommendations. Additionally, the research team were responsible for the drafting of the 
guidelines and the resourcing of the guideline development group. The working of the group 
can be characterised as a dynamic process where an understanding of the pros and cons of CHE Discussion Paper 164 
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treatment emerges and is refined, questions are responded to with available evidence and 
uncertainties are assessed.  A detailed report of the working of the guidelines groups has been 
published. [28] 
Levels of Evidence and Strength of Recommendation 
To make a critical assessment of information on clinical effectiveness for evidence-based 
guidelines, reviewers follow a process of establishing the level of evidence that individual 
studies provide.  Papers are categorised according to study design reflecting susceptibility to 
bias, and questions are answered using the best evidence available.  Evidence categories, 
shown in Table 1, are adapted from the US Agency for Health Care Policy and Research 
Classification. [29] 
 
Table 1: Categories of Evidence 
Ia:  evidence from meta-analysis of randomised controlled trials 
Ib:  evidence from at least one randomised controlled trial 
IIa:  evidence from at least one controlled study without randomisation  
IIb:  evidence from at least one other type of quasi-experimental study 
III:  evidence from non-experimental descriptive studies, such as comparative 
studies, correlation studies and case-control studies 
IV:  evidence from expert committee reports or opinions and/or clinical 
experience of respected authorities 
 
When considering a question of the effect of an intervention, if the question can be answered 
by category I evidence provided by a meta analysis or randomised controlled trial then 
studies of weaker design (e.g. controlled studies without randomisation) are not reviewed. 
Recommendations are graded A to D as shown in Table 2, though categories of evidence do 
not always map easily onto a certain strength of recommendation.  First, it is possible to have 
methodologically sound (category I) evidence about an area of practice that is clinically 
irrelevant or has such a small effect that it is of little practical importance and therefore 
attracts a lower strength of recommendation.  Second, a statement of evidence may only 
cover one part of an area in which a recommendation has to be made, or evidence of similar 
quality may be contradictory. To produce comprehensive recommendations, a group has to 
extrapolate from the available evidence and this sometimes leads to lower strength 
recommendations based upon category I evidence. [4]  In addition to the strength of clinical 
evidence, recommendations reflect the applicability of the evidence to the population of 
interest; economic considerations; guideline developers’ awareness of practical issues; and 
(inevitably) guideline developers’ societal values. [29] NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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Table 2: Strength of Recommendation 
A  directly based on category I evidence 
B  directly based on category II evidence or extrapolated recommendation from 
category I evidence 
C  directly based on category III evidence or extrapolated recommendation from 
category I or II evidence 
D  directly based on category IV evidence or extrapolated recommendation from 
category I, II or III evidence 
 
To apply a strength of recommendation to cost information presents some difficulties.  For 
example, it is possible that a large, well-conducted trial may estimate some overall resource 
savings for a new treatment, but unless these findings are generalisable to normal care they 
may not reflect the best evidence possible.  Moreover, resource measurement taken from 
other sources, for example insurance claims databases, may be subject to unknowable 
influences, particularly selection biases, and similarly not provide a reliable view.  
Commonly, in health care, alternative treatment strategies feature small differences in 
outcome.  Consequently, precise and internally valid trials are required not just to achieve a 
reliable measure of differences in health outcome, but also (correlated) differences in 
resource consequences.  The approach adopted by the guidelines group for cost 
recommendations was to apply the same categories of evidence used for effectiveness to 
resource use and additionally, to establish the generalisability and relevance of findings by 
mapping their consequences onto current national patterns of resource use.  For example, the 
SOLVD trial, for the treatment of heart failure with an ACE-inhibitor, [30] reported rates of 
hospitalisation for heart failure in the placebo group consistent with rates reported nationally 
for England.  Hence, the reduction in hospitalisation in the active treatment group was 
consistent with improved health outcomes reported in the trial and plausible in the English 
setting. In the guidelines groups, strengths of recommendations for cost-effectiveness were, 
therefore, determined by the categories of evidence for both resource use and health outcome, 
as well as the generalisability of those data.  The grade attached was determined by the 
overall quality of evidence as interpreted by the group.  
Handling costs 
While a social perspective in economic evaluation is both desirable and formally correct, in 
practice, due to the (un)availability of data, analyses of cost were limited to those borne by 
the NHS.  Cost data used in guidelines were those in the public domain; it was beyond the 
scope of the guidelines development process to conduct new costing studies.   
The approach is incrementalist, thinking of the net costs and consequences of changes in 
practice.  Costs were calculated by attaching published average national unit costs (with the 
exception of drugs: see below) to resource items.  Economists often argue that, for decision-
making purposes, marginal costs are preferable to average costs. [31]  While the problems CHE Discussion Paper 164 
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associated with average unit costs are recognised, there is no generally valid or accepted 
method for presenting marginal costs on items or procedures: these will vary from locality to 
locality.  The simple presentation of analyses permits decision-makers to apply different unit 
costs where such information is locally available.  Reflating of unit costs from different years 
of origin, to a common year, to adjust for health care cost changes over time, was not 
conducted.  In general, there was no more than a two year gap between the oldest and newest 
values.  Additionally, reflating is an ambiguous practice for certain items such as drug costs 
where, under UK reimbursement, the price tends to remained fixed over substantial periods 
of time. 
Data on drugs 
It is not the role of a guideline group to conduct original research, rather to synthesise 
obtainable information.  However, in three of the four areas (ie, excluding ACE-inhibitors), 
Prescribing Analysis and Cost (PACT) data were obtained from the Prescription Pricing 
Authority (PPA). These data provide the total number of prescriptions reimbursed and their 
cost for each drug.  Because prescriptions may not adequately describe the volume of use of 
drugs, [32] quantity data were adjusted using World Health Organisation tables of defined 
daily doses, to provide a measure of the patient years of prescribing reimbursed. [33] These 
are not necessarily the doses recommended in the British National Formulary, [34] but are 
intended to reflect the average maintenance dose in adults.  Where WHO values were not 
available, the standard lower maintenance dose listed in the British National Formulary was 
used.  Hence, it was possible to calculate the volume of use of each drug as well as 
comparative acquisition costs of drugs per patient for a set period of treatment (reflecting the 
mix of forms of each drug currently prescribed). 
Examples of the guidelines 
The full guidelines give a systematic presentation of the available evidence in each treatment 
area and the treatment recommendations derived by the guidelines groups.  Here we present 
shortened summaries of two of the guidelines alongside selected recommendations, to 
illustrate issues for the inclusion of cost-effectiveness information in guideline development. 
Guideline 1: ACE-inhibitors for Heart Failure 
Introduction 
Heart failure is a common, chronic condition with a very poor prognosis: as much as half of 
patients with a diagnosis of heart failure may die within 4 years.  However, only 20-30% of 
patients assessed by British general practitioners (GPs) as having heart failure are prescribed 
an ACE-inhibitor. Most patients who are investigated for heart failure receive chest x-ray and 
electrocardiography but only about a third undergo echocardiography.  Diagnosis by clinical 
assessment has been estimated to be correct in about half of cases when confirmed by echo-NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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cardiogram.
   While it is possible that some patients are being inappropriately treated, it is 
likely that ACE-inhibitors are considerably under-utilised in patients who might benefit from 
them. 
Effectiveness data 
Trials of ACE-inhibitors use left ventricular ejection fraction measured by an 
echocardiogram to detect heart failure.  A meta-analysis of 39 studies found that the pooled 
relative risk of mortality using a fixed effects model was 0.83 (95% CI 0.76 to 0.90) when 
taking an ACE-inhibitor compared to placebo.  The findings of the meta-analysis are 
consistent with the largest trial, SOLVD, which randomised 2569 patients with overt but 
stabilised heart failure and a left ventricular ejection fraction of 35% or less to enalapril or 
placebo with average follow-up of about 41 months. [30] The average benefit from ACE-
inhibitors estimated during the SOLVD trial was 2.4 months of extended life. 
Quality of life data 
Narang and colleagues (1996) [35] reviewed aspects of quality-of-life reported in 35 double-
blind studies, including 3411 symptomatic patients, comparing the effect of ACE-inhibitors 
and placebo.  Exercise duration improved in 23 of 35 (66%) studies while symptoms 
improved in 25 of 33 (76%) studies. All 9 studies with a sample size of more than 50, a 
follow-up of 3-6 months and using a treadmill exercise test, showed improved exercise 
capacity as well as symptoms.  
The single largest and most general assessment of patient quality of life comes from a 
subsidiary analysis of the SOLVD treatment and prevention trials. [36]  This found interim 
improvements in self-assessed dyspnoea and social functioning in those patients treated with 
ACE-inhibitors that were statistically significant, although statistical significance did not 
persist for the full 2 years of follow-up. Another analysis of SOLVD symptomatic patient 
data using observed frequency of dyspnoea showed a statistically significant reduction 
achieved and maintained beyond 2 years for those patients treated with enalapril compared to 
those treated with placebo. [37] 
Resource and cost data 
Trials consistently show a reduction in hospitalisation for progressive heart disease when on 
ACE-inhibitor therapy. It is unclear whether these are lasting reductions or simply reflect a 
‘time-window’ effect;  with more patients on ACE-inhibitors completing the trial follow-up 
period without their heart disease progressing, but deteriorating in following years. The data 
do not suggest that greater hospitalisation for other reasons offsets reduced heart failure 
hospitalisation; ACE-inhibitors seem to have a positive effect on other-cause hospitalisation 
in symptomatic patients. It is not generally safe to assume that hospitalisation rates found in 
trials will be matched in clinical practice. As already noted, the hospitalisation rate in the 
control arm of the SOLVD treatment trial matches the average rate reported nationally for 
England.  Each GP could expect, on average, four inpatient cases with heart failure each year 
and SOLVD trial data suggest that ACE-inhibition might prevent (or delay) one of these 
hospitalisations.  CHE Discussion Paper 164 
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The annual cost of purchasing ACE-inhibitors (at maintenance doses) ranges from £100-£340 
per year, considering doses reported in the British National Formulary.  The incremental cost 
per patient using ACE-inhibitors in primary care may vary from a small cost saving through 
to a net cost of nearly £1600 over four years (see Table 3).  In cost-effectiveness terms, it is 
likely that ACE-inhibitors for heart failure fall in the approximate range £0 - £10,000 per life 
year gained, given the range of assumptions listed and the remaining uncertainties.  The 
important variables are the cost of the ACE-inhibitor itself and hospitalisation savings.  It is 
not possible in this simple model to explore the influence of compliance with therapy on the 
cost-effectiveness estimates presented.  The trial data, analysed on an intention-to-treat basis, 
reflect the level of compliance achieved in the SOLVD trial; the degree to which this 
represents experience in general practice in the UK is uncertain.  Where non-compliance 
involves withdrawal of prescription then both costs and benefits are foregone and the overall 
cost-effectiveness ratios are not significantly altered.  Substantial cross-over to ACE-inhibitor 
therapy in the placebo group in the SOLVD trial may mean the attributable benefits are 
underestimated. NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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Table 3: Net cost and benefit per patient of ACE-i for Heart Failure. 
Assumptions (optimistic or conservative) [1]:  Optimistic  Conservative 
ACE-inhibitor £100/year or 340/year for four years   £400  £1400 
Initiation of therapy by 2 GP visits or 2 outpatient visits [2]  £20  £138 
Reduced hospitalisation or no reduced hospitalisation [3]  -£626  £0 
GP visits related to heart failure unchanged or 1 extra visit/year for 
four years [4] 
£0 £40 
Net cost range  -£206  £1578 
Increased life expectancy (based on placebo comparison) [5]  0.203 years  0.203 years 
Incremental cost-effectiveness of implementing ACE-inhibitor 
therapy [6] 
Small cost saving 
and health gain 
£7770 / life year 
gained 
 
[1]  Costs and benefits are shown which arise from the addition of ACE-i to current care. Diagnosis costs are 
excluded because of the variation in tests performed, the lack of adequate cost data and because these costs 
may occur in any case as part of normal care.  For simplicity of presentation the consequences of treatment 
withdrawal are not modelled, hence drug costs are likely to be over-estimated. 
[2] Cost  per: 
  GP consultation £10 (excluding prescribing cost): Netten and Dennett, 1997.[38] 
Outpatient visit £69: CIPFA/HFM, 1997 [39] 
  Costs of additional blood tests are excluded as no adequate cost data was found. 
[3]  Calculation based on: 
  Difference in SOLVD trial treatment and control hospitalisation rates (21.9%-15.4%) x 4 years; 
Inpatient stay of 14.5 days (McMurray 1993) [40]; 
Cost of an inpatient day £166: CIPFA/HFM, 1997 [39] 
[4]  Since patients visit their GPs, on average, once a year in relation to heart failure it is not plausible to 
assume an optimistic reduction in GP visits although treatment does delay disease progression and 
associated morbidity. 
[5]  Based on the placebo-controlled findings of the SOLVD treatment trial, improved survival was highly 
statistically significant (p = 0.0036 by stratified log rank test).  However, the survival gain calculation 
(using Irwin’s Restricted Mean) does not provide a useful confidence interval.  The point estimate is thus 
used in optimistic and conservative scenarios. 
[6]  Survival gains are truncated in the SOLVD trial, and it is reasonable to presume that if treatment stopped 
there would be some additional benefit after cessation of therapy. This is not modelled, since it is probable 
that therapy would continue and so both costs and benefits would occur after 4 years. CHE Discussion Paper 164 
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Commentary 
Within the effectiveness data, no extrapolation beyond the period of the trials has been 
attempted.  The presentation of available evidence is relatively free of assumptions, and it is 
easy to explore values different from the ones used.  The values presented reflected those felt 
appropriate by the group in discussion.  It would, technically, have been better to make a 
fractional reduction in the drug costs over four years to reflect mortality.  However, such an 
adjustment made no difference to the substantive findings and the group preferred the 
simplicity of the presentation shown.  The purpose of the analysis was to confirm to the 
guidelines group that not only were the individual attributes of treatment favourable, but also 
the ‘ball-park’ cost-effectiveness.  If treatment stopped at four years, there would be some 
additional benefit after cessation of therapy and the findings presented would be 
conservative, though it is probable that therapy would continue, and that both costs and 
benefits would occur after four years. Future costs and benefits were not discounted because 
of the short, four year time frame and because all important costs are distributed along with 
the benefit in time. Neither extrapolation nor discounting will substantially alter the cost-
effectiveness ratios presented. 
The strength of recommendation (Box 4) for the cost-effectiveness of ACE-inhibitors for 
heart failure reflects both that worthwhile health benefits have been established in trials as 
well as the net impact upon resources (from the SOLVD trial) which appears generalisable to 
the English context.  
 
Box 4: Selected recommendations from the heart failure guideline. 
•  All patients with symptomatic heart failure and evidence of impaired left ventricular 
function should be treated with an ACE-inhibitor (A). 
•  Treatment of heart failure with ACE-inhibitors is cost-effective (A). 
•  As there is no good evidence of clinically important differences in the effectiveness of 
available ACE-inhibitors, patients should be treated with the cheapest drug that they can 
use effectively (B). 
Guideline 2: NSAIDs for Osteoarthritis 
Introduction 
On average, approximately 3% of patients on general practice lists will be recorded as 
suffering from osteoarthritis, but osteoarthritis being one of a continuum of connective tissue 
disorders, the extent to which these inter-relate and share common treatment is uncertain.  
The prevalence of all such conditions (ICD 710-739) amounts to nearly 19% of patients. 
Currently, GPs in England spend approximately £150 million each year on Non-Steroidal 
Anti-Inflamatory Drugs (NSAIDs) for musculoskeletal and joint disorders.  Annually, this 
corresponds to nearly 1.5 million person-years of treatment, with ibuprofen and diclofenac NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
  16
constituting respectively 26% and 37% of prescribed usage.  (Prescribed use of ibuprofen is 
likely to be an underestimate of overall use due to its over-the-counter availability.)  
Although they enjoy very extensive use in UK general practice, attempts to derive an 
evidence-based rationale to choose between NSAIDs has not proven fruitful.  This is because 
of the poor quality of trials comparing different NSAIDs, which exhibit many biases. [41, 42]  
The guideline addressed a more fundamental question, raised by the group of general 
practitioners:   when is it appropriate to use NSAIDs in preference to simple analgesia?  
Thus, the guideline addresses the decision to manage pharmacologically painful joints 
believed to be due to degenerative arthritis.   
Effectiveness data 
There are only three adequately designed trials [43-45] which may, in combination, provide 
useful information about the appropriate place of NSAID use in primary care.  These studies 
examine the relative short term effectiveness (4-6 weeks) of the NSAIDs Ibuprofen and 
Naproxen against paracetamol in the treatment of osteoarthritis of the knee [43, 44] or the 
NSAID diclofenac versus co-proxamol in the treatment of non traumatic pain in one or two 
of the hip, knee, ankle or wrist joints. [45]  In addition, the Bradley study compares ibuprofen 
at ‘analgesic dose’ or at ‘anti-inflammatory dose’ with paracetamol.   
These studies indicate small benefits for NSAIDs over simple analgesia for pain at rest and 
pain in motion, using a visual analogue scale, but no significant change in time to walk 50 
feet.  One study, Parr et al [45] used the Nottingham Health Profile to describe different 
elements of the comparison between diclofenac and co-proxamol on broader health 
outcomes; the results suggest that there are no substantial differences in outcome for simple 
analgesia versus NSAIDs. 
Compliance and safety data 
Comparing NSAIDs and simple analgesia, treatment discontinuation was slightly less 
common for patients taking an NSAID, although the difference was not statistically 
significant. Overall, 3.3% (95% CI -1.2% to 7.7%) fewer patients dropped out of NSAID 
therapy over an average of 4.5 months of treatment.   
The absolute level of risk associated with individual NSAIDs and their safety relative to 
paracetamol is unknown. In a large US trial, the control group of patients took a variety of 
different NSAIDs for rheumatoid arthritis. [46]  In this cohort, the number needed to treat for 
a 6 month period to expect one serious gastrointestinal event was 105 (95% CI 81 to 151), 
though it is unclear to what extent this risk is attributable to NSAIDs.  Placebo controlled 
studies of aspirin in heart disease indicate that, while gastrointestinal disease is common in 
patients, the additional disease attributable to NSAIDs may be relatively small. [3]   
Comparing the use of ibuprofen to no NSAID use, various case-control studies have 
estimated the rate of serious gastrointestinal damage to vary from no additional risk to a 
relative risk of two. [47] 
The guideline group were unable to uncover any evidence to indicate the absolute risk of 
attributable side effects of paracetamol-based analgesics (compared to no analgesia use) in 
primary care patients with osteoarthritic pain. CHE Discussion Paper 164 
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The relative risk of serious gastrointestinal complications with individual NSAIDs is 
reviewed systematically by Henry and colleagues [48] who examine the relationship between 
drug use and admission to hospital.  The review identifies 12 epidemiological controlled 
studies examining 14 NSAIDs for which comparison with ibuprofen can be made.  Ibuprofen 
presents the lowest risk, and is used as a baseline to rank the relative safety of the other 
NSAIDs, although most differences are non-significant and the findings vulnerable to a range 
of biases.  The review also suggests that the risk of gastrointestinal injury increases for higher 
doses of the same NSAID.   
Resource and cost data 
Paracetamol appears a cost-effective alternative to any NSAID because of lower acquisition 
cost and relative absence of gastrointestinal toxicity, while often providing adequate 
symptomatic relief and displaying similar levels of patient withdrawal from treatment.  For 
the three NSAIDs for which randomised control trial data comparing with simple analgesia 
are available, the Henry [48] study suggests an ordering, on safety grounds, of ibuprofen, and 
then diclofenac or naproxen.  While diclofenac and naproxen are similarly priced, ibuprofen 
is three to four times cheaper, given the forms in which these drugs are currently prescribed.  
Therefore, in the likely event that ibuprofen results in lower gastrointestinal injury and 
symptomatology, and without clear evidence of a general therapeutic advantage for naproxen 
or diclofenac, ibuprofen is the most cost-effective first-line NSAID. 
There is wide variation in the purchase costs of different preparations of the same NSAID 
available on the NHS. There is no evidence to support the use of more expensive preparations 
over cheaper ones or the use of the modified release preparations. 
In those patients requiring NSAID treatment it is important to consider what strategies may 
be available to minimise the risk of gastrointestinal injury.   Such preventative strategies 
should not be confused with treatment of (common) dyspepsia where prescription or over-
the-counter purchase of antacids may be considered when NSAID treatment cannot be 
modified.  
Preventing NSAID induced gastro-intestinal injury 
Concerns about the high risk of NSAID-induced gastrointestinal injury have led to a number 
of trials of H2-receptor antagonists (such as cimetidine and ranitidine), and misoprostol.  A 
recent meta analysis of trials focusing upon endoscopic assessment of lesions demonstrated a 
statistically significant reduction in the number of NSAID induced gastric ulcers in patients 
randomised to take misoprostol, but not those taking H2 blockers. [49]  Both H2 blockers and 
misoprostol reduced the risk of duodenal ulcers in long term but not short term 
administration.  However, it is recognized that endoscopically detected lesions may 
overestimate clinically important injury. 
A recent large, double-blind trial randomised primary and secondary care patients, with 
rheumatoid arthritis and receiving NSAIDs, to receive misoprostol or placebo. [46]  The trial 
assessed the development of serious upper gastrointestinal complications detected by clinical 
symptoms or findings (rather than scheduled endoscopy) and found a small but borderline NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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significant reduction in favour of the use of misoprostol.  Twenty-five of 4404 patients 
receiving misoprostol, and 42 of 4439 patients receiving placebo suffered a serious upper 
gastrointestinal complication (odds ratio: 0.60; 95% CI 0.35 to 1.00 by Gart exact method) 
during six months of follow-up.  The number needed to treat to prevent one serious 
gastrointestinal complication in this period is 264 (95% CI 132 to 5703).  In the first month 
of the study 5% more patients taking misoprostol withdrew, primarily because of diarrhoea 
and other side effects. 
A rate of serious gastrointestinal events necessitating hospitalisation for rheumatoid arthritis 
patients, associated with NSAID therapy, and preventable by misoprostol, can be estimated 
(Table 4). 
Table 4: Rates of serious gastrointestinal events with and without misoprostol in  
rheumatoid arthritis patients taking NSAIDs (derived from Silverstein, 1995) [46] 
Treatment No  of 
patients 




misoprostol+ 4404  6  months  2202  25  0.0114 
placebo 4439  6  months  2220  42  0.0189 
* Serious GI events definitely attributable to NSAID use 
+ Average daily dose 680µg 
 
Hence, for 1000 patient years of treatment, 7.6 events will be prevented (95% CI 0.4-15.1), at 
a purchase cost of misoprostol of £230,000 (using the average dose reported in the trial).  The 
net cost/event prevented is calculated, and the confidence interval of events prevented is used 
to provide low and high estimates (Table 5). 
 
Table 5: Net cost and serious gastrointestinal events prevented with  









Net cost  Cost/event 
avoided 
High 0.4  £230,000  £1,200  £228,800  £572,000 
Best guess  7.6  £230,000  £22,800  £207,200  27,300 
Low 15.1  £230,000  £45,300  £184,700  £12,200 
* The average cost of inpatient hospitalisation across all specialities was £3000/episode for 
Scotland in 1995/6. [50] 
 
The rate of serious gastrointestinal complications in the control group in the Silverstein trial 
was 1.9% per person-year of treatment.  Extrapolation using the number of person-years of CHE Discussion Paper 164 
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treatment currently prescribed in England implies 30,000 hospitalisations for NSAID-
associated gastrointestinal injury per year.  Thus, half of the 60,000 annual gastrointestinal 
ulcer/bleed associated hospitalisations in England [51] might be estimated to be NSAID-
associated.  Inclusion of over-the-counter NSAID use might suggest a bigger proportion.  
There were 4304 ulcer-associated deaths (ICD 531-3) in England in 1991.  Assuming that 
chance of fatality following hospitalisation is independent of the underlying reason for 
gastrointestinal injury, then 2150 deaths per year can be attributed to NSAID-associated 
injury, or 1.38 deaths per year in 1000 patients taking an NSAID for one year.  This suggests 
that nearly one in 10 serious gastrointestinal complications are fatal.  The use of misoprostol 
led to a 40% relative reduction in serious events (95% CI 64%-2%) and so might be argued 
to lead to a 40% reduction in the average fatality rate.  These figures are used to estimate the 
cost-effectiveness of a general policy of misoprostol prophylaxis in terms of the cost per life 
saved (Table 6).  High and low estimates are derived assuming lives saved are a constant 
fraction of serious events avoided. 
 
Table 6: Modelled cost-effectiveness of misoprostol prophylaxis 
(for 1000 treated patients) 
Scenario  Net cost  Lives saved*  Cost/life-saved 
High 228,800  0.0276  £8,290,000 
Best guess  207,200  0.552  £375,000 
Low 184,700  0.883  £209,000 
* [High, best guess, low] estimate calculated as [2%, 40%, 64%] of 1.38 respectively (see 
text). 
 
The above estimates must be viewed as tentative, given the assumptions required to reach 
them.  For example, hospitalisation rates are generally higher in the US than in the UK, and 
the relationship between hospitalisation and mortality with ulcers of different underlying 
cause is unknown; notably there is currently no direct evidence of gastrointestinal injury-
associated death being prevented by misoprostol prophylaxis.  The purchase cost of 
misoprostol reflects additional separate prescription of misoprostol tablets.  Combined 
NSAID and misoprostol tablets are available: subtracting the cost of non-proprietary forms of 
these NSAIDs, the combined drugs are generally a more expensive way of providing 
misoprostol, and if used will increase the net cost. 
The mean ages of death in men and women due to ulcer, haemorrhage and perforation (ICD-
9: 531-3) are 76 and 81 respectively.  The average life-expectancy in the normal population 
for both genders at this age is about eight years, [52] so a crude calculation of cost per year of 
life gained is possible using estimates in Table 4.  The age distribution of ulcer fatalities 
presented in national statistics aggregates those ulcers caused by NSAIDs, those related to 
Helicobacter Pylori, and those due to other causes.  These causes would need to be separated, NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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and other modelling assumptions validated, before formal calculation of years-of-life saved is 
possible. 
On the available evidence extrapolated from a trial of rheumatoid arthritis patients, it is not 
demonstrated that a strategy of routine and unselected misoprostol prophylaxis for patients 
taking NSAID therapy is cost-effective.  Patient review and sequential therapy selection 
beginning with simple analgesia, is likely to minimise adverse event rates in the general 
patient group. 
It is possible, although not demonstrated, that misoprostol prophylaxis may be more cost-
effective in a high risk group for which current NSAID therapy has to be maintained.  The 
Silverstein trial of rheumatoid arthritis patients suggested greater relative risks of serious 
gastrointestinal injury for patients with age >75 (Odds ratio [OR]=2.48), history of peptic 
ulcer (OR=2.29), gastrointestinal bleeding (OR=2.56) and heart disease (OR=1.84).  These 
risks factors have been presented in such a manner that it is not possible to calculate absolute 
reductions in the rates of serious events for each high risk group, and the numbers of events 
in each instance are small.  Without these, costs per life saved for high risk groups cannot be 
estimated, but none of the risk factors individually appear very important, and the cost 
effectiveness of misoprostol prophylaxis in high risk NSAID-user groups remains 
undemonstrated. 
Although it appears likely that omeprazole may be similar in effectiveness to misoprostol in 
NSAID-induced ulcer prophylaxis and healing, [53] and better tolerated (although purchase 
costs are also higher), trials that rely on ulcers detected through endoscopy overestimate the 
effectiveness (and hence value) of protective agents in practice. No large, pragmatically 
designed trials with serious gastrointestinal events as primary outcome are available for 
omeprazole.  Without such data it is not possible to recommend the routine use of 
omeprazole prophylaxis as an evidence-based strategy. 
Commentary: 
The guideline group were not using the available evidence to rule out any drug given for 
osteoarthritis, since the evidence regarding any of the consequences of these treatments is not 
compelling.  Instead, on the basis of broad arguments about superiority or (near) equivalence 
of attributes, they established a sequencing of treatment:  
1  Paracetamol is cheaper than ibuprofen, has most of the efficacy, is nearly as well 
tolerated, and is safer at therapeutic dose. 
2  Ibuprofen is cheaper than diclofenac or naproxen, is not known to be less efficacious, and 
is probably safer. 
3  Other NSAIDs are similarly more expensive and less safe than ibuprofen, and their 
relative efficacy to analgesia is not know. 
The underlying quality of evidence is reflected in the strengths of recommendations in Box 5. 
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Box 5: Selected recommendations from the osteoarthritis guideline. 
•  In terms of cost-effectiveness, patients presenting with painful joints believed to be due to 
degenerative arthritis should initially be treated with be paracetamol.  If inadequate 
symptomatic relief is obtained, then ibuprofen is the most cost effective alternative (C).   
•  Modified release preparations are relatively expensive, while no evidence demonstrates 
that they are more effective than standard therapy; therefore they should not be used (D).  
•  Prophylactic protective therapy (with misoprostol or proton pump inhibitors) should not 
be used routinely as it is not cost effective for the reduction of serious gastric events (D).   
•  There are a group of patients who are at higher risk of upper gastrointestinal bleeding or 
perforation for whom prophylaxis may be cost-effective but further evidence is required 
(D). 
 
The group also wished to explore the appropriateness of prophylactic treatment in patients 
who were at risk of gastrointestinal injury and for whom symptomatic relief could only be 
obtained with an NSAID.  Given the lack of direct evidence, the group requested a modelling 
exercise to explore the likely value of treatment and having been led through the model, with 
all its uncertainties, the group felt confident that the case for a general policy of prophylaxis 
had not been established. 
RESEARCH ISSUES 
The four guidelines developed have some important similarities.  Each addresses a highly 
focused question on the use of one, or several, classes of drug for the treatment of one 
condition in primary care.  Each guideline assesses the available evidence using quantitative 
techniques appropriate to the task of informing the guidelines group.  These factors may limit 
the value of the methodology presented in this paper in other contexts.   
Certain areas of medicine are not amenable to quantitative analysis and may only be 
summarised by narrative review.  An example may be where individual trials for a medical 
condition use different intermediate endpoints or outcomes.  The need for narrative review 
will also increase as the focus shifts from treatment of one defined condition to the 
management of a whole disease.  In these cases, the health economic component may be 
restricted to equivalence and dominance messages and not be able to offer clear advice where 
an alternative achieves (possibly conflicting signs of) a marginally greater effect at additional 
cost.  Where the benefits of diagnostic procedures and treatments are patchy or unclear, it 
may prove difficult to set these against the costs of implementation. 
The process of grading recommendations of costs alongside health consequences raised some 
interesting issues in the guideline groups, particularly in areas of uncertainty or broad 
equivalence of effect.  An example came in the overall consideration of the relative value of 
Selective Serotonin Reuptake Inhibitor (SSRI) or tricyclic treatment in first line treatment of 
depression.  The effects of the treatments are broadly equi-poised with the evidence NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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suggesting tricyclics are slightly more efficacious and SSRIs slightly better tolerated.  A 
range of secondary claims concerning the advantages of SSRIs were explored (for example, 
they are safer in overdose than some but not all tricyclics) and were thought to be of minor 
worth, except where overdose was a genuine concern.  In the light of inconclusive 
differences, it would be intuitive to suppose that any treatment recommendation favouring (if 
at all) either SSRIs or tricyclics would attract a low strength of recommendation.  However, 
when the group had considered the net cost implications of using SSRIs instead of tricyclics 
they were certain that the additional costs were not worthwhile in the light of such uncertain 
benefits.  Should the cost-effectiveness grading reflect the uncertainty of the treatment effect, 
the certainty of the cost consequence, or an amalgam?  Ultimately, the strength of 
recommendation reflected not just the quality of evidence but the guideline group’s 
understanding of the importance of the message.  An alternative would be to treat costs and 
effects separately and develop different grading systems for cost evidence statements and 
recommendations.  Then two grades would be attached to any cost-effectiveness 
recommendation.  This would be at the expense of the simplicity of the method presented 
here, where a recommendation encodes the overall importance of a message. 
The levels of evidence attached to the resource consequences of treatments mirrored those 
used for clinical effectiveness.  The validity, susceptibility to bias, and generalisability of 
different sources of resource data is, ultimately, an empirical question and different 
viewpoints are possible.  Adoption of a different system would again suggest movement 
towards separate grading of costs and treatment effects. 
Many clinical guidelines currently in the public domain do not address health economic 
concepts.  It is possible to envisage retrospective inclusion of economic analyses in such 
guidelines and this raises the issue of whether the health economist needs to be present at all 
at the time of guideline development. A concern with retrospective ‘bolting-on’ of economic 
analyses is the (often) complex issues of managing patients and delivering health care 
alongside the technical nature of the treatments themselves.  Health economists need to 
understand these issues and reflect them in their analyses; additionally, it would appear to be 
a retrograde step to pass off an important opportunity to work so closely with clinicians and 
other health care professionals. 
 
DISCUSSION 
Incorporating economic data into evidence-based guidelines introduces some methodological 
challenges: specifically in providing valid, generalisable cost estimates, in the grading of cost 
‘evidence’, and in finding a presentation helpful to clinicians.  The guideline development 
process reported here presents an attempt to address these issues.   
In recognition of the disparate level and nature of information available for each of the 
treatment areas, a profile approach was adopted to set out the attributes of treatment.  
Evidence concerning the effectiveness, quality-of-life, compliance, safety and health service 
delivery and resource use associated with treatment options was presented and discussed in 
the guideline groups.  A recurring theme in these discussions was GPs attempts to derive CHE Discussion Paper 164 
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useful statements of how treatments would affect patients.  In the case of ACE-inhibitors, the 
pooled relative risk of survival, reported in placebo-controlled trials, conveyed little and the 
average increase in life-expectancy was more helpful, though even this caused some debate, 
since the average increase masked a wide variation in benefit for individual patients.  It is 
possible that clinicians find not just the results of economic analyses but clinical trials 
themselves difficult to put into the context of treating individual patients.  Interestingly, the 
GPs in the group seemed comfortable moving from the very solid evidence presented on the 
value of ACE-inhibitors to the very speculative exploration of prophylaxis against NSAID-
induced ulcer, reported here, when they themselves were participants in the steps and 
assumptions.  A concern would be whether other clinicians outside the group could make 
such an investment to understand the issues. 
Traditional summary presentations of cost-effectiveness were made, where available data 
permitted, but these provided only a partial view of the value of treatment.  For example, the 
analysis of ACE-inhibitors in symptomatic heart failure suggests between £0 and £10,000 per 
life-year gained.  These values do not inform on the quality of extended life or how the 
quality of existing life of patients might be improved when receiving an ACE-inhibitor.  
Clinicians asserted that the provision of simple presentations of the attributes of treatment 
and how these were aggregated was most useful: results could be unpicked permitting other 
clinicians to apply their own values.  
When reaching recommendations, the clinicians appeared to require treatments to leap two 
broad hurdles: first did the treatment option really work (i.e. did changes in health and risks 
of consequent adverse events support the use of a treatment and could these benefits be 
delivered in practice); and then second, was the purchase worthwhile (for the benefits 
involved, what was the net requirement in health resource costs, and where did the costs and 
savings occur)?  Additionally, they wanted an independent appraisal of the likely bounds of 
uncertainty for the various attributes of treatment (e.g. the likely range of the size of clinical 
effect and the likely range of the cost of achieving this effect). 
The raison d’être of economic evaluation has (largely) been to achieve greater efficiency in 
health care delivery. In none of the areas examined was there adequate data to make an 
informative estimation of a cost/QALY.  Even if such calculation had been possible, it is 
unclear how much additional value would have been attached to this information. Instead, the 
clinicians approached decisions by thinking about treatment attributes and by using the two-
hurdle approach described above.  This may reflect an appropriate response to the disparate 
effects of treatment, some good - some bad, requiring a different cognitive model.  Seldom 
can a treatment’s value be adequately captured by a simple, cost-effectiveness construct and 
it is apparent that the general practitioners in the group were not working with a pre-defined 
notion of ‘worthwhile’ in the way that health-economists often approach concepts of 
efficiency.  By contributing to the ‘clinical group consciousness’ of a guideline development 
group, it may be possible to influence treatment recommendations to appropriately consider 
concepts of cost-effectiveness, consistent with clinical decision-making processes. An 
overview is provided in Table 7 both for health economists becoming involved in guidelines 
work, and for guideline developers considering including a health economist. NICEly does it: economic analysis within evidence-based clinical practice guidelines. 
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The definition of a valid guideline is one that, when followed, leads to the costs and benefits 
it predicts.  This emphasises the need to use the best evidence available to produce the most 
valid guidelines and a variety of effective strategies to help clinicians to implement them.  By 
these means, if economic issues are appropriately incorporated, then they will maximise cost-
effectiveness in the limited way that current information permits.   CHE Discussion Paper 164 
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Table 7: An overview of guidelines development for health economists 
•    
•  It is important to be clear about the process and objectives of guidelines work, the conduct of group meetings and 
the role of each of the group members. 
   
•  Objective (if probabilistic) attributes of treatment decisions include effectiveness, side-effects, compliance, safety, 
quality-of-life, health service delivery issues and resource use.  The outcomes of a guidelines process are graded 
treatment recommendations which may reflect some or all of these attributes.   
 
•  The health economist, together with other group facilitators, has a responsibility of providing a rigorous exploration 
of treatment attributes with the available evidence.  A general understanding of other disciplines (statistics, 
epidemiology and health services research) is essential alongside a training in economic evaluation methodology. 
 
•  Simple and transparent presentations, which permit exploration with different values, are most likely to be helpful to 
the guideline group and subsequent users of the guideline.  
 
•  Each attribute of treatment is assessed in turn on its own merits including bounds of uncertainty. Over-precision 
should be challenged and all uncertainties should be explored which are appropriate to the data or expressed in the 
group. 
 
•  Careful presentation and full discussion in the guidelines group is essential for an understanding of the attributes of 
treatment to evolve into a view of overall clinical importance.  Data, although rigorously analysed are being used to 
put a treatment in a broad ‘ball-park’ with respect to its various attributes (e.g. safe, acceptable, effective, 
deliverable, cost-neutral).   
 
•  The importance attached to each attribute of treatment remains the responsibility of the guideline group as a whole 
and recommendations must be transparent and credible to the target audience.  The process of aggregating up to an 
overall recommendation may be facilitated by a summary table of attributes, and presenting summary cost-
effectiveness estimates when appropriate.  Summary ratios need careful explanation and interpretation.  
 
•  A systematic review of previously conducted economic analyses relating to a treatment may provide useful 
background to the health economist but may have limited (or no) direct use in the guidelines process.  If rigorously 
conducted, the guidelines process is likely to produce an understanding and evaluation of treatment inadequately 
reflected in any one published analysis.   
 
•  The scope for conducting traditional cost-effectiveness models may be limited or unhelpful in some therapeutic 
areas, especially where the various attributes of treatments contain conflicting messages.  Where modelling is 
appropriate, clinicians appear more responsive to simple and transparent models, than to complex ‘black box’ 
methods requiring greater assumptions and extrapolation. 
 
•  Grading of recommendations of cost-effectiveness is in its infancy.  However, the grade of recommendation should 
reflect not only precision and susceptibility to bias of data but also generalisability.  
 
•  As with clinical effectiveness, it is acceptable to say ‘we just don’t know yet’ in a recommendation about cost-
effectiveness of treatment and that more precise data is required.NICEly does it: economic analysis within evidence-based clinical practice guidelines 
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NICEly DOES IT 
 
Evidence-based cost-effectiveness guidelines are a fledging science with methodological 
development ongoing.  However, it must be this ‘science’ that NICE is seen to communicate 
to the NHS, without modification for political ends.  Cost containment guidelines are likely 
to have no currency with the medical profession.  Credible guidelines stand the best chance 
of achieving an appropriate use of resources.  For example, a recent guideline considering the 
use of Donepezil Hydrochloride for the treatment of Alzheimer’s Disease concluded on the 
basis of the available phase II and III trials that there was currently insufficient evidence to 
recommend its use, or to continue secondary care initiated prescribing. [54] 
For products approaching the licensing stage, NICE plans to require access to trial data four 
months before product launch.  Appraisal will follow a Development and Evaluation 
Committee (DEC) style procedure using a Cost per Quality-Adjusted Life-Year framework 
(Cost/QALY) rather than a guideline approach.  The major problem with cost-utility studies 
has always been the quality and handling of limited data. [24]  How will NICE achieve a 
robust assessment of new technologies on the basis of trial data intended for licensing?  In 
internal deliberations the most heroic assumptions will be required and as regards the 
external audience of practising clinicians, a cost-utility framework does not contain the right 
information to advise treatment decisions.  
A simplified, evidence-based guideline process may be possible when considering close 
analogue and ‘me-too’ products at the near licensing stage.  In four months, little more will 
be possible.  To assess new pharmaceuticals and procedures in the context of the 
epidemiology of the disease, other available treatments and health service delivery issues 
may place insurmountable strain upon the appraisal process.  An annual target of 30 to 50 
appraisals and guidelines is evidently ambitious.  The consequent danger is that the appraisal 
process will have to cut corners in the very circumstances where a full guideline is most 
needed.  Tampering with the elements of the evidence-based clinical guideline process may 
threaten their validity and consequent authority in clinical decision-making. [27, 55]  Where 
longer term data are required, a continuing-research period, either following or delaying the 
NHS reimbursement decision, is proposed - although how this will work is as yet unknown.  
A full guideline process would ensure the right questions are asked of any further research.  
NICE should focus on evaluating medicines in robust and physical terms rather than 
calculating assumption-laden QALYs. If the science wins then the guidelines process may 
become an implicit but effective fourth hurdle for pharmaceuticals in the UK. 
The ability of any guidelines to effect a substantial change in clinical practice remains a 
research issue.  The decision-making environment will, in any case, change in England due to 
the introduction of clinical governance: a package of activities to ensure clinicians receive 
and act upon the best evidence concerning treatment, corporately monitor their performance 
and report to those with overall responsibility.  
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The impact of implementing guidelines 
Substantial use is to be made of audit methodologies in informing the clinical governance 
process.  To this end, NICE ‘will develop a range of audit methodologies that can be adapted 
for local use to support the guidance it produces’. Actual monitoring will come under the 
‘National Framework for Assessing Performance’ initiative, led by the new Commission for 
Health Improvement (CHI).  Although it sounds straightforward, there are a number of major 
informational challenges in implementing this model. [56]  It will prove unrealistic to follow 
all clinical activities: instead tracer conditions will need to be identified, although these may 
vary from year to year.  Information may be relatively easy to obtain for some activities: use 
of drugs in primary care, use of procedures in secondary care, and even some simple outcome 
data (e.g. 30-day operative mortality).  However, appropriate use of these interventions (i.e. 
whether the right patient received the right intervention at the right time) may prove 
considerably more difficult and require linkage across different patient records.   
Simply handing NICE guidelines to clinicians would not be expected, on current evidence, to 
achieve substantial appropriate changes in health care.  Clinical governance is intended to 
create a pincer against unacceptable variations in performance, and the government will 
consider introducing new powers for NICE and CHI if problems persist.  This reflects a 
belief that acceptable and unacceptable variations in practice are generally separable.  The 
evidence for the appropriate use of many treatments provided by the NHS is inadequate and it 
is unclear how far such a strategy can be pursued. The government may need to consider the 
dual issues of measurability and enforceability implicit in its’ reforms. Clinical governance as 
described signals a shift away from clinical freedom and towards protocol-driven health care. 
Guideline methodology has been developed to improve the scientific basis of decision-
making; guidelines have never been intended for mechanistic use or to form the basis of legal 
argument about defensible health care. 
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